IL-2 immunotherapy does not benefit patients taking antiretrovirals.
D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000276:immunology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D007376:Interleukin-2; D011994:Recombinant Proteins; C082598:aldesleukin